SEOUL, Korea
The Korea-based international pharmaceutical company, SK Biopharmaceuticals, and the Korea-based emerging biotech, AriBio, announced that they entered into a collaboration agreement for SK Biopharmaceuticals’ novel new small molecule SKL-G that is being developed for the treatment of glaucoma.
Dr. Christopher Gallen, CEO and President of SK Biopharmaceuticals, said, “While focused on the disorders and mechanisms of the nervous system, the powerful SK Biopharmaceuticals Third Wave discovery platform creates compounds that are also relevant to diseases in other body systems, in this case, the eye. Through this agreement, both companies can realize a creative drug development process by sharing R&D capabilities, know-how, and experiences.”
Dr. Soo-Hyun Sung, CEO and President of AriBio, said, “This agreement recognizes AriBio’s capabilities in drug discovery and development for ophthalmologic disorders. Also, it is an excellent example of collaboration between a medium-sized venture company and a major conglomerate.”
SK Biopharmaceuticals has discovered this innovative drug candidate and has evaluated its potential in animal models with AriBio since 2012. The animal experiments showed that SKL-G successfully prevented optic nerve cell death and, in addition, lowered intraocular pressure that is one of the major causes of glaucoma.
Most currently-marketed glaucoma drugs have only symptomatic treatment effects, lowering intraocular pressure, but they fail to address the disease process itself, eventually resulting in blindness. Thus fundamental therapies that can prevent optic nerve cell death represent an enormous unmet medical need.
Because the evaluation results fully supported the competitive advantage of SKL-G over existing therapies, the decision was made to form a strategic alliance for preclinical and clinical development.
SK biopharmaceuticals and AriBio have agreed to complete preclinical development shortly and then start clinical trials following an Investigational New Drug (IND) application to US FDA. They are also considering various strategic options for partnering and commercialization.
The market size for glaucoma treatments is estimated to be over $3 billion in 2010, and the market might be quite larger if other ophthalmology disorders such as age-related macular degeneration are considered.
About SK Biopharmaceuticals
SK Biopharmaceuticals is a global pharmaceutical company that was spun out in April 2011 from SK Holdings, the third-largest conglomerate in South Korea. SK Biopharmaceuticals focuses on the discovery and development of new drugs for the treatment of central nervous system disorders. SK Biopharmaceuticals also provides custom services for the manufacture and sales of active pharmaceutical ingredients as well as produces intermediates of drugs for global pharmaceutical companies at its facility in Daejeon, South Korea. The plant has been approved by the Korean FDA for the production of active pharmaceutical ingredients under current Good Manufacturing Practices.
SK Biopharmaceuticals leads all Korean pharmaceutical companies with 14 authorized INDs in the U.S. SK Biopharmaceuticals has a preclinical research and development center located in Daejeon, South Korea, corporate offices in Seoul, South Korea, commercial and partnering offices in Shanghai, China, and its business development and clinical research center in New Jersey for the clinical development of its assets in the areas of epilepsy, neuropathic pain, depression, schizophrenia, chronic constipation, Parkinson’s disease, and Alzheimer’s disease.
For more information, visit www.skbp.com.
About AriBio
AriBio is one of the emerging biotech companies in Korea specializing in new drug development in various areas with high unmet medical needs such as ophthalmology. AriBio is currently developing more than ten drug candidates.
For more information, visit www.aribio.com.
CONTACT
SK Life Science
Business Development
Duncan Taylor,
201-421-3842
dtaylor@sklsi.com
